HCPLive Network

New Guidance Issued for Atrial Fibrillation

The American Heart Association (AHA), American College of Cardiology (ACC), and the Heart Rhythm Society (HRS) have issued updated guidelines on the management of patients with atrial fibrillation (AF) that include recommendations on new oral anticoagulants. The guidance replaces the previous full document released in 2006 and 2 focused updates from 2011.
 
The new guidelines rate dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) alongside warfarin as recommended for patients with nonvalvular AF with a history of stroke or transient ischemic attack or an otherwise elevated risk of stroke.
 
"Because what we say in the guideline can affect how a drug is used, we were careful to be even-handed and evidence-based in presenting new drugs," Craig T. January, MD, PhD, professor of Medicine in the Division of Cardiovascular Medicine at the University of Wisconsin-Madison, a fellow of the ACC, a member of the AHA and HRS, and chair of the writing committee, said in a statement. "Our goal was to provide useful, non-biased information."
 
For AF patients who have mechanical heart valves, the guidelines recommend warfarin, and the target International Normalized Ratio (INR) intensity (2.0 to 3.0 or 2.5 to 3.5) should be based on the type and location of the prosthesis.
 
The guidelines also advise clinicians use one of the newer anticoagulants for patients who can’t maintain a therapeutic INR between 2.0 and 3.0 on warfarin.
 
Dabigatran should not be used in patients with a mechanical heart valve, and dabigatran and rivaroxaban are not recommended for use in patients with end-stage chronic kidney disease or who are on hemodialysis.
 
Preferences were not provided for any of the 3 newer agents because there is a lack of head-to-head trials. Choice of antithrombotics should be based on shared decision making that considers risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics.
 
The guidelines are to be published in the Journal of the American College of Cardiology, Circulation, Journal of the American Heart Association, and Heart Rhythm.

Further Reading
The US Food and Drug Administration (FDA) announced it will give priority review status to Amgen’s application to market ivabradine as a treatment for chronic heart failure. The drug works to slow the heart rate in appropriate patients without causing negative effects on cardiac rhythms. It was developed by Les Laboratoires Servier in Suresnes, France, and first approved by the European Medicines Agency (EMA) as Procoralan in 2005. According to Servier, a global pharmaceutical firm, Procoralan (also sold as Corlentor) is available in 102 countries.
As the nation tries to cut its health-care costs critics of reform have worried that some patients who need expensive though risky procedures like coronary artery bypass graft surgery (CABG) might not get them. But a new Harvard School of Public Health study could allay those fears.
Low levels of enrollment and more favorable risk profiles for participants raise questions about whether the findings of clinical trials are generalizable to typical patients with myocardial infarction, according to research published in the Aug. 27 issue of the Journal of the American Medical Association.
For patients with first unprovoked venous thromboembolism, aspirin after anticoagulant treatment reduces the risk of recurrence, according to a study published online Aug. 25 in Circulation.
Self-monitoring with self-titration of antihypertensive medications is associated with lower blood pressure for patients with hypertension at risk for cardiovascular disease, according to a study published in the Aug. 27 issue of the Journal of the American Medical Association.
The nation’s youth, and its smoke-free air need federal protection from vapors from e-cigarettes, according to a set of recommendations released Aug. 25 by the American and Heart Association.
Cognitive impairment is associated with an increased risk of subsequent stroke, according to a meta-analysis published online Aug. 25 in CMAJ, the journal of the Canadian Medical Association.
More Reading